GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cipher Pharmaceuticals CPH.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

13.75

+1.78%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cipher Pharmaceuticals

Its shares trade on Toronto Stock Exchange under the ticker CPH.TO. It has been listed since 25 February 2004. In the fiscal year to 31 December 2025, it reported revenue of $51.3m and net income of $27.8m. At that date it held total assets of $156.2m and shareholders' equity of $126.0m.

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm has a portfolio of commercial and late-stage products. The company operates in the specialty pharmaceuticals segment. The company acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. The company operates in Canada and the United States.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 Feb 2004
Employees
6

Leadership

Pay as last reported

  • Mr. Craig MullChairman of the Board, Interim Chief Executive Officer, since 2019C$768,476
  • Mr. Bryan JacobsChief Financial OfficerC$418,246
  • Dr. Diane GajewczykVice President - Scientific and Medical AffairsC$436,742
  • Mr. Arthur DeboeckDirectorC$51,536
  • Mr. Christian GodinIndependent DirectorC$66,536
  • Ms. Cathy SteinerIndependent DirectorC$58,203
  • Mr. Harold WolkinIndependent DirectorC$82,386

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.